Cannabis Science Inc (fka CBIS)

[Smokin Moose]

Cannabis and Cancer - list of references Part 3
401. Mechoulam, R. & Hanu, L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite
promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6, 67-73 (2001).
402. Ramer, R., Brune, K., Pahl, A. & Hinz, B. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem Biophys Res Commun 286, 1144-1152 (2001).
403. Recht, L. D. et al. Antitumor effects of ajulemic acid (CT3), a synthetic non- psychoactive cannabinoid. Biochem Pharmacol 62, 755-763 (2001).
404. ElSohly, M. A., deWit, H., Wachtel, S. R., Feng, S. & Murphy, T. P. Delta9- tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 25, 565-571 (2001).
405. Jamshidi, N. & Taylor, D. A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134, 1151-1154 (2001).
406. Roth, M. D. et al. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24, 339-344 (2001).
407. Tashkin, D. P. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 7, 43-61 (2001).
408. Pagotto, U. et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86, 2687-2696 (2001).
409. Day, T. A., Rakhshan, F., Deutsch, D. G. & Barker, E. L. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59, 1369-1375 (2001).
410. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323, 13-16 (2001).
411. Moody, J. S., Kozak, K. R., Ji, C. & Marnett, L. J. Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry 40, 861-866 (2001).
412. Maccarrone, M., Attina, M., Cartoni, A., Bari, M. & Finazzi-Agro, A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 76, 594-601 (2001).
413. Velasco, L., Ruiz, L., Sanchez, M. G. & Diaz-Laviada, I. delta(9)- Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 268, 531-535 (2001).
414. Darmani, N. A. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198-203 (2001).
415. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene- dependent tumor growth. FASEB J 15, 2745-2747 (2001).
416. Jacobsson, S. O., Wallin, T. & Fowler, C. J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299, 951-959 (2001).
417. Smith, S. R., Terminelli, C. & Denhardt, G. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur J Pharmacol 425, 73-83 (2001).
418. Di Marzo, V. et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358, 249-255 (2001).
419. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. J Neurosci Res 65, 346-353 (2001).
420. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Schneider, C. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. J Biol Chem 276, 30072-30077 (2001).
421. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61, 5784-5789 (2001).
422. Sarafian, T. A., Tashkin, D. P. & Roth, M. D. Marijuana smoke and Delta(9)- tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol Appl Pharmacol 174, 264-272 (2001).
423. Esposito, G., Izzo, A. A., Di Rosa, M. & Iuvone, T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J Neurochem 78, 835-841 (2001).
424. Jonsson, K. O., Vandevoorde, S., Lambert, D. M., Tiger, G. & Fowler, C. J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 133, 1263-1275 (2001).
425. Jacobsson, S. O. & Fowler, C. J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132, 1743-1754 (2001).
426. Bisogno, T. et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem 268, 1982-1989 (2001).
427. Ripamonti, C. & Dickerson, E. D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61, 955-977 (2001).
428. Guzman, M., Sanchez, C. & Galve-Roperh, I. Control of the cell survival/death decision by cannabinoids. J Mol Med 78, 613-625 (2001).
429. Kaferstein, H. & Sticht, G. Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl. Forensic Sci Int 113, 353-357 (2000).
430. Di, M., Bisogno, T. & De Petrocellis, L. Endocannabinoids: new targets for drug development. Curr Pharm Des 6, 1361-1380 (2000).
431. Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406, R5-7 (2000).
432. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275, 31938-31945 (2000).
433. Klein, T. W., Lane, B., Newton, C. A. & Friedman, H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225, 1-8 (2000).
434. Carriot, F. & Sasco, A. J. [Cannabis and cancer]. Rev Epidemiol Sante Publique 48, 473-483 (2000).
435. Maccarrone, M., Salvati, S., Bari, M. & Finazzi-Agro. Anandamide and 2- arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. Biochem Biophys Res Commun 278, 576-583 (2000).
436. De Petrocellis, L., Melck, D., Bisogno, T. & Di Marzo, V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 108, 191-209 (2000).
437. Ho, B. Y. et al. Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology 141, 1675-1685 (2000).
438. MacCarrone, M. et al. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. Eur J Biochem 267, 2991-2997 (2000).
439. Molnar, J. et al. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer Res 20, 861-867 (2000).
440. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6, 313-319 (2000).
441. Zhu, L. X. et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165, 373-380 (2000).
442. Puffenbarger, R. A., Boothe, A. C. & Cabral, G. A. Cannabinoids inhibit LPS- inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69 (2000).
443. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126 (2000).
444. Yea, S. S., Yang, K. H. & Kaminski, N. E. Role of nuclear factor of activated T- cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther 292, 597-605 (2000).
445. Jacobsson, S. O., Rongard, E., Stridh, M., Tiger, G. & Fowler, C. J. Serum- dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60, 1807-1813 (2000).
446. Rubino, T. et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39, 1331-1336 (2000).
447. Gomez del Pulgar, T., Velasco, G. & Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347, 369-373 (2000).
448. Han, D. S. et al. Synthesis and cytotoxic effects of deoxy-tomentellin. Arch Pharm Res 23, 121-127 (2000).
449. Benard, J. [Cannabinoids, among others, send malignant glial tumors to nirvana.]. Bull Cancer 87, 299-300 (2000).
450. Muthian, S., Nithipatikom, K., Campbell, W. B. & Hillard, C. J. Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier. J Pharmacol Exp Ther 293, 289-295 (2000).
451. Smith, S. R., Terminelli, C. & Denhardt, G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti- inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293, 136- 150 (2000).
452. Di Marzo, V., Melck, D., De Petrocellis, L. & Bisogno, T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat 61, 43-61 (2000).
453. Lorenzo Fernandez, P. [Potential therapeutic usefulness of cannabis and cannabinoids]. An R Acad Nac Med (Madr) 117, 595-605; discussion 616-24 (2000).
454. Ruiz, L., Miguel, A. & Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458, 400-404 (1999).
455. Lambert, D. M. et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1440, 266-274 (1999).
456. Gorter, R. W. Cancer cachexia and cannabinoids. Forsch Komplementarmed 6 Suppl 3, 21-22 (1999).
457. Mechoulam, R. Recent advantages in cannabinoid research. Forsch Komplementarmed 6 Suppl 3, 16-20 (1999).
458. listed], [N. a. Studies of high-dose chemotherapy with stem cell support for breast cancer. Am J Health Syst Pharm 56, 940 (1999).
459. Valk, P. J. et al. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. J Virol 73, 3595-3602 (1999).
460. Mukhopadhyay, S., Cowsik, S. M., Lynn, A. M., Welsh, W. J. & Howlett, A. C. Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: structural requirements determined by peptide analysis. Biochemistry 38, 3447-3455 (1999).
461. Sarafian, T. A., Magallanes, J. A., Shau, H., Tashkin, D. & Roth, M. D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol 20, 1286-1293 (1999).
462. Basavarajappa, B. S. & Hungund, B. L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N- arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem 72, 522- 528 (1999).
463. Melck, D. et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262, 275-284 (1999).
464. Kenney, S. P. et al. Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 181, 491-497 (1999).
465. Masset, D., Bourdon, J. H., Arditti-Djiane, J. & Jouglard, J. [Impact of delta-9- tetrahydrocannabinol and its metabolites on the immune system]. Acta Clin Belg Suppl 1, 39-43 (1999).
466. Berglund, B. A., Boring, D. L. & Howlett, A. C. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol 469, 527-533 (1999).
467. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. & Guzman, M. Delta9- tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436, 6-10 (1998).
468. Di Marzo, V. et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett 436, 449-454 (1998).
469. Maccarrone, M. et al. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 273, 32332-32339 (1998).
470. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40, 179-185 (1998).
471. Herrstedt, J., Aapro, M. S., Smyth, J. F. & Del Favero, A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6, 204-214 (1998).
472. Bisogno, T. et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. Eur J Biochem 254, 634-642 (1998).
473. Baek, S. H. et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 21, 353-356 (1998).
474. Bruera, E. & Neumann, C. M. The uses of psychotropics in symptom management in advanced cancer. Psychooncology 7, 346-358 (1998).
475. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95, 8375-8380 (1998).
476. Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248, 515-522 (1998).
477. Zurier, R. B. et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 41, 163-170 (1998).
478. Derocq, J. M. et al. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 425, 419-425 (1998).
479. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331, 15-19 (1998).
480. Di Toro, R., Campana, G., Sciarretta, V., Murari, G. & Spampinato, S. Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. Life Sci 63, PL197-204 (1998).
481. Ongradi, J., Specter, S., Horvath, A. & Friedman, H. Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. Pathol Oncol Res 4, 191-199 (1998).
482. Bisogno, T., Sepe, N., De Petrocellis, L., Mechoulam, R. & Di Marzo, V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 239, 473-479 (1997).
483. Molina-Holgado, F., Lledo, A. & Guaza, C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8, 1929-1933 (1997).
484. Voth, E. A. & Schwartz, R. H. Medicinal applications of delta-9- tetrahydrocannabinol and marijuana. Ann Intern Med 126, 791-798 (1997).
485. McPartland, J. M. & Pruitt, P. L. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med 3, 39-45 (1997).
486. Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322, 671-677 (1997).
487. Abood, M. E., Ditto, K. E., Noel, M. A., Showalter, V. M. & Tao, Q. Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol 53, 207-214 (1997).
488. Ruh, M. F., Taylor, J. A., Howlett, A. C. & Welshons, W. V. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 53, 35-41 (1997).
489. Deutsch, D. G. et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231, 217-221 (1997).
490. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. & Kaminski, N. E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142, 278-287 (1997).
491. Sanchez, C., Velasco, G. & Guzman, M. Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Res 767, 64-71 (1997).
492. Axelrod, R. S. Antiemetic therapy. Compr Ther 23, 539-545 (1997). 493. Goodman, M. Risk factors and antiemetic management of chemotherapy-induced
nausea and vomiting. Oncol Nurs Forum 24, 20-32 (1997).
494. Hunter, S. A. & Burstein, S. H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci 60, 1563-1573 (1997).
495. Di Marzo, V., De Petrocellis, L., Sugiura, T. & Waku, K. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-
arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem Biophys Res Commun 227, 281-288 (1996).
496. Lew, G. M. Tau protein after delta-9-tetrahydrocannabinol in a human neuroblastoma cell line. Gen Pharmacol 27, 1141-1143 (1996).
497. NIH. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)- Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser S 446, 1-317 (1996).
498. Bhargava, H. N., House, R. V., Thorat, S. N. & Thomas, P. T. Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol. Pharmacology 52, 271-282 (1996).
499. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30, 109-117 (1996).
500. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316, 977-984 (1996).
501. Ho, B. Y. & Zhao, J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci Lett 212, 123-126 (1996).
502. Zheng, Z. M. & Specter, S. C. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. Int J Immunopharmacol 18, 53-68 (1996).
503. Abood, M. E. & Martin, B. R. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 39, 197-221 (1996).
504. Mackie, K., Lai, Y., Westenbroek, R. & Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15, 6552- 6561 (1995).
505. Burnette-Curley, D. & Cabral, G. A. Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9tetrahydrocannabinol. Proc Soc Exp Biol Med 210, 64-76 (1995).
506. Burstein, S. H. & Hunter, S. A. Stimulation of anandamide biosynthesis in N- 18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). Biochem Pharmacol 49, 855-858 (1995).
507. Klein, T. W., Newton, C., Zhu, W., Daaka, Y. & Friedman, H. delta 9- Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 209, 205-212 (1995).
508. Fride, E. et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 272, 699-707 (1995).
509. Gibertini, M., Newton, C., Friedman, H. & Klein, T. W. IL-1 beta and TNF alpha modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice. Pharmacol Biochem Behav 50, 141-146 (1995).
510. Hirst, R. A. & Lambert, D. G. Do SH-SY5Y human neuroblastoma cells express cannabinoid receptors? Biochem Soc Trans 23, 418S (1995).
511. Cabral, G. A., Toney, D. M., Fischer-Stenger, K., Harrison, M. P. & Marciano- Cabral, F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 56, 2065-2072 (1995).
512. Nelson, K., Walsh, D., Deeter, P. & Sheehan, F. A phase II study of delta-9- tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10, 14-18 (1994).
513. Koutek, B. et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 269, 22937-22940 (1994).
514. Kusher, D. I., Dawson, L. O., Taylor, A. C. & Djeu, J. Y. Effect of the psychoactive metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. Cell Immunol 154, 99- 108 (1994).
515. Zheng, Z. M. & Specter, S. Suppression by delta-9-tetrahydrocannabinol of lipopolysaccharide-induced and intrinsic tyrosine phosphorylation and protein expression in mouse peritoneal macrophages. Biochem Pharmacol 47, 2243-2252 (1994).
516. Trisler, K. & Specter, S. Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes. Int J Immunopharmacol 16, 593-603 (1994).
517. Vigano, A., Watanabe, S. & Bruera, E. Anorexia and cachexia in advanced cancer patients. Cancer Surv 21, 99-115 (1994).
518. Cabral, G. A. & Fischer-Stenger, K. Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. Life Sci 54, 1831-1844 (1994).
519. Shivers, S. C., Newton, C., Friedman, H. & Klein, T. W. delta 9- Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sci 54, 1281-1289 (1994).
520. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 365, 61-65 (1993).
521. Mackie, K., Devane, W. A. & Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44, 498-503 (1993).
522. Klein, T. W., Newton, C., Widen, R. & Friedman, H. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267, 635-640 (1993).
523. Melvin, L. S. et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 44, 1008-1015 (1993).
524. Bruera, E. Is the pharmacological treatment of cancer cachexia possible? Support Care Cancer 1, 298-304 (1993).
525. Bouaboula, M. et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214, 173-180 (1993).
526. Fischer-Stenger, K., Dove Pettit, D. A. & Cabral, G. A. Delta 9- tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post- translational events. J Pharmacol Exp Ther 267, 1558-1565 (1993).
527. Burnette-Curley, D., Marciano-Cabral, F., Fischer-Stenger, K. & Cabral, G. A. delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. Int J Immunopharmacol 15, 371- 382 (1993).
528. Tchekmedyian, N. S., Halpert, C., Ashley, J. & Heber, D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. JPEN J Parenter Enteral Nutr 16, 88S-92S (1992).
529. Zheng, Z. M., Specter, S. & Friedman, H. Inhibition by delta-9- tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int J Immunopharmacol 14, 1445-1452 (1992).
530. Mackie, K. & Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89, 3825-3829 (1992).
531. Mitchelson, F. Pharmacological agents affecting emesis. A review (Part I). Drugs 43, 295-315 (1992).
532. Caulfield, M. P. & Brown, D. A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106, 231-232 (1992).
533. Bruera, E. Current pharmacological management of anorexia in cancer patients. Oncology (Huntingt) 6, 125-30; discussion 132, 137 (1992).
534. Campbell, M. & Bateman, D. N. Pharmacokinetic optimisation of antiemetic therapy. Clin Pharmacokinet 23, 147-160 (1992).
535. Nahas, G. & Latour, C. The human toxicity of marijuana. Med J Aust 156, 495-497 (1992).
536. Bruera, E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49 Suppl 2, 35-42 (1992).
537. Turkanis, S. A., Karler, R. & Partlow, L. M. Differential effects of delta-9- tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells. Brain Res 560, 245-250 (1991).
538. Wang, M., Richards, A. L., Friedman, H. & Djeu, J. Y. Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9- tetrahydrocannabinol. J Leukoc Biol 50, 192-197 (1991).
539. Watzl, B., Scuderi, P. & Watson, R. R. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol 288, 63-70 (1991).
540. Watzl, B., Scuderi, P. & Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 13, 1091-1097 (1991).
541. Tashkin, D. P. Pulmonary complications of smoked substance abuse. West J Med 152, 525-530 (1990).
542. Johnson, B. A. Psychopharmacological effects of cannabis. Br J Hosp Med 43, 114- 6, 118-20, 122 (1990).
543. Stewart, D. J. Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol 68, 304-313 (1990).
544. Tortorice, P. V. & O'Connell, M. B. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10, 129-145 (1990).
545. Howlett, A. C., Scott, D. K. & Wilken, G. H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem Pharmacol 38, 3297-3304 (1989).
546. Shook, J. E. & Burks, T. F. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 249, 444-449 (1989).
547. Grunberg, S. M. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev 3, 216-221 (1989).
548. McCabe, M. et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6, 243-246 (1988).
549. Dill, J. A. & Howlett, A. C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 244, 1157-1163 (1988).
550. Kawakami, Y. et al. Suppression by delta-9-tetrahydrocannabinol of interleukin 2- induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int J Immunopharmacol 10, 485-488 (1988).
551. Triozzi, P. L. & Laszlo, J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs 34, 136-149 (1987).
552. Little, P. J., Kaplan, N. C. & Martin, B. R. Pharmacological profile of delta 9-THC carbamate. Alcohol Drug Res 7, 517-523 (1987).
553. Howlett, A. C. Regulation of adenylate cyclase in a cultured neuronal cell line by marijuana constituents, metabolites of delta-9-tetrahydrocannabinol, and synthetic analogs having psychoactivity. NIDA Res Monogr 79, 148-157 (1987).
554. Roffman, R. A. Stress inoculation training in the control of THC toxicities. Int J Addict 21, 883-896 (1986).
555. Specter, S. C. et al. Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. Int J Immunopharmacol 8, 741- 745 (1986).
556. Dodds, L. J. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 10, 143-166 (1985).
557. Citron, M. L. et al. Antiemetic efficacy of levonantradol compared to delta-9- tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 69, 109-112 (1985).
558. Perlin, E. et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci 74, 171-174 (1985).
559. Ungerleider, J. T. et al. THC or Compazine for the cancer chemotherapy patient-- the UCLA study. Part II: Patient drug preference. Am J Clin Oncol 8, 142-147 (1985).
560. Bakowski, M. T. Advances in anti-emetic therapy. Cancer Treat Rev 11, 237-256 (1984).
561. Kaplan, N. C. Dichloroethyl carbamoyl ester of delta-9-tetrahydrocannabinol. Chemical synthesis and biological testing and evaluation as a potentially site- specific anti-tumor agent. Sci Sin [B] 27, 1048-1058 (1984).
562. Hiller, E. & Gerhartz, H. [New aspects in the antiemetic therapy of cytostatic drug- induced vomiting]. Klin Wochenschr 62, 441-445 (1984).
563. Stoudemire, A., Cotanch, P. & Laszlo, J. Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis. Arch Intern Med 144, 1029-1033 (1984).
564. Eyre, H. J. & Ward, J. H. Control of cancer chemotherapy-induced nausea and vomiting. Cancer 54, 2642-2648 (1984).
565. Frytak, S., Moertel, C. G. & Rubin, J. Metabolic studies of delta-9- tetrahydrocannabinol in cancer patients. Cancer Treat Rep 68, 1427-1431 (1984).
566. Hogan, P., Sharpe, M., Smedley, H. & Sikora, K. Cannabinoids and hCG levels in patients with testicular cancer. Lancet 2(8359), 1144 (1983).
567. Treffert, D. A. & Joranson, D. E. delta 9-Tetrahydrocannabinol and therapeutic research legislation for cancer patients. JAMA 249, 1469-1472 (1983).
568. Carey, M. P., Burish, T. G. & Brenner, D. E. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99, 106-114 (1983).
569. Laszlo, J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 25 Suppl 1, 1-7 (1983).
570. Heim, M. E. [Cannabis and cannabinoids. Possibilities of their therapeutic use]. Fortschr Med 100, 343-346 (1982).
571. Tetrahydrocannabinol (THC) for cancer patients. A review of the National Cancer Institute program in Wisconsin. Wis Med J 81, 24 (1982).
572. Laszlo, J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 9 Suppl B, 3-9 (1982).
573. Ungerleider, J. T. et al. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50, 636-645 (1982).
574. Joss, R. A. et al. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemother Pharmacol 9, 61-64 (1982).
575. Goldstein, M. S. & Williams, F. F. How we comply with federal guidelines on THC dispensing. Pharm Times 47, 32-36 (1981).
576. Poster, D. S., Penta, J. S., Bruno, S. & Macdonald, J. S. delta 9- tetrahydrocannabinol in clinical oncology. JAMA 245, 2047-2051 (1981).
577. Anderson, P. O. & McGuire, G. G. Delta-9-tetrahydrocannabinol as an antiemetic. Am J Hosp Pharm 38, 639-646 (1981).
578. Procedure for obtaining THC for cancer patients. JAMA 246, 15-19 (1981).
579. Sweet, D. L., Miller, N. J., Weddington, W., Senay, E. & Sushelsky, L. delta 9- Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 21, 70S-75S (1981).
580. Garb, S. Cannabinoids in the management of severe nausea and vomiting from cancer chemotherapy. Some additional considerations. J Clin Pharmacol 21, 57S- 59S (1981).
581. Benowitz, N. L. & Jones, R. T. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21, 214S-223S (1981).
582. Dow, G. J. & Meyers, F. H. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy. J Clin Pharmacol 21, 128S-132S (1981).
583. Abraham, D., Pina, K. R. & Davignon, J. P. Mechanism for national distribution of delta 9-tetrahydrocannabinol (NSC-134454). J Clin Pharmacol 21, 122S-127S (1981).
584. Scigliano, J. A. THC therapeutic research by independent and state-sponsored investigators: a historical review. J Clin Pharmacol 21, 113S-121S (1981).
585. Penta, J. S., Poster, D. S., Bruno, S. & Macdonald, J. S. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 21, 11S-22S (1981).
586. Levitt, M. et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 21, 103S- 109S (1981).
587. Gunby, P. Many cancer patients receiving THC as antiemetic. JAMA 245, 1515, 1518 (1981).
588. Chang, A. E. et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47, 1746-1751 (1981).
589. Sallan, S. E. & Cronin, C. M. Is THC an effective antiemetic for cancer patients? Opinion 2. CA Cancer J Clin 30, 283-285 (1980).
590. Frytak, S. Is THC an effective antiemetic for cancer patients? Opinion 1. CA Cancer J Clin 30, 278-282 (1980).
591. Winokur, S. H., Baker, J. J., Lokey, J. L. & Price, N. A. Marijuana for nausea and vomiting in cancer patients. J Med Assoc Ga 69, 919-920 (1980).
592. Lucas, V. S. J. & Laszlo, J. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 243, 1241-1243 (1980).
593. Sallan, S. E., Cronin, C., Zelen, M. & Zinberg, N. E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9- tetrahydrocannabinol and prochlorperazine. N Engl J Med 302, 135-138 (1980).
594. Levy, J. A. & Heppner, G. H. Immunosuppression by marihuana and its cannabinoid constituents. J Immunopharmacol 2, 159-177 (1980).
595. Ekert, H., Waters, K. D., Jurk, I. H., Mobilia, J. & Loughnan, P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9- tetrahydrocannabinol. Med J Aust 2, 657-659 (1979).
596. Frytak, S. et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91, 825-830 (1979).
597. Chang, A. E. et al. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91, 819-824 (1979).
598. Mechoulam, R. & Carlini, E. A. Toward drugs derived from cannabis. Naturwissenschaften 65, 174-179 (1978).
599. Warner, W., Harris, L. S. & Carchman, R. A. Inhibition of cortiocosteroidogenesis by delta-9-tetrahydrocannabinol. Endocrinology 101, 1815-1820 (1977).
600. Friedman, M. A. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. Cancer Biochem Biophys 2, 51-54 (1977).
601. White, A. C., Munson, J. A., Munson, A. E. & Carchman, R. A. Effects of delta9- tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl Cancer Inst 56, 655-658 (1976).
602. Carchman, R. A., Harris, L. S. & Munson, A. E. The inhibition of DNA synthesis by cannabinoids. Cancer Res 36, 95-100 (1976).
603. Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L. & Carchman, R. A. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55, 597-602 (1975).
604. Noyes, R. J., Brunk, S. F., Avery, D. A. & Canter, A. C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18, 84-89 (1975).
605. Noyes, R. J., Brunk, S. F., Baram, D. A. & Canter, A. Analgesic effect of delta-9- tetrahydrocannabinol. J Clin Pharmacol 15, 139-143 (1975).